Medical/Pharmaceuticals

Vela Diagnostics' SARS-CoV-2 RT-PCR Test v2.0 Authorized for Emergency Use in the U.S.

FAIRFIELD, N.J., Sept. 23, 2020 /PRNewswire/ -- Vela Diagnostics announced today that the ViroKey™ SARS-CoV-2 RT-PCR Test v2.0 has obtained the Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). This automated probe-based reverse transcription PCR test detects SAR...

2020-09-23 12:53 1245

Genor Biopharma Announces Proposed Listing on the Main Board of SEHK

HONG KONG, Sept. 23, 2020 /PRNewswire/ -- JHBP (CY) Holdings Limited ("Genor Biopharma"or the "Company"; stock code: 6998.HK), a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs, announced the proposed listing of its shares on the...

2020-09-23 12:00 854

Eurisotop Responds to Market Demand for Deuterated Chloroform

SACLAY, France, Sept. 22, 2020 /PRNewswire/ -- Eurisotop, a wholly owned subsidiary of Cambridge Isotope Laboratories, Inc. (CIL), announced a capacity expansion of its deuterated chloroform production. Since its acquisition by CIL in 2001, Eurisotop has become a leading producer of deuterated NM...

2020-09-22 22:00 1533

Jennewein Biotechnologie GmbH and Chr. Hansen A/S to join forces in high-growth Human Milk Oligosaccharides market

RHEINBREITBACH and BONN, Germany, Sept. 22, 2020 /PRNewswire/ -- Jennewein Biotechnologie GmbH agreed to join forces with Chr. Hansen Holding A/S, a leading bioscience company based in Hoersholm/Denmark, to lead the global market for human milk oligosaccharides (HMOs). Chr. Hansen entered into an...

2020-09-22 21:36 1877

Biorasi Commended by Frost & Sullivan for its Full-service Offering to Drive Rare Disease Patient Recruitment for CROs

SANTA CLARA, California, Sept. 22, 2020 /PRNewswire/ -- Based on its recent analysis of the North American contract research organization (CRO) market, Frost & Sullivan recognizesBiorasi, LLC with the 2020 North American Entrepreneurial Company of the Year Award. Biorasi's milestone-based, patie...

2020-09-22 21:00 1377

Switching to investigational once-weekly insulin icodec from other basal insulins demonstrated to be efficacious and well-tolerated for people with type 2 diabetes in phase 2 trial

BAGSVAERD, Denmark, Sept. 22, 2020 /PRNewswire/ -- Today, Novo Nordisk announced results from three phase 2 clinical trials for insulin icodec, an investigational once-weekly basal insulin analogue, which were presented during the 56th European Association for the Study of Diabetes (EASD) Annual ...

2020-09-22 20:53 1429

New Study Suggests GlycoMark® May Identify Highest Risk Patients with Prediabetes

RALEIGH, North Carolina, Sept. 22, 2020 /PRNewswire/ -- According to new data presented at the 56th European Association for the Study of Diabetes (EASD) annual meeting, the GlycoMark blood test reflects beta-cell functional mass, which is important in identifying prediabetic individuals with the...

2020-09-22 19:00 1198

TCM Lianhua Qingwen Capsule approved for registration in Mauritius

SHIJIAZHUANG, China, Sept. 22, 2020 /PRNewswire/ -- Yiling Pharmaceutical Co., Ltd. (SHE: 002603) announced on Tuesday that it has received a registration approval issued by the Ministry of Health and Wellness ofMauritius, indicating Lianhua Qingwen Capsule has been registered in accordance with ...

2020-09-22 15:21 673

Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma

SYDNEY, Sept. 22, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with Dana-Farber Cancer Institute (DFCI) inthe United States, to investigate the use of...

2020-09-22 09:21 6542

Israeli Pain Monitoring Startup Medasense Raises $18M in Series C Round

Accelerating Commercialization of its Novel Pain Monitoring Solutions RAMAT GAN, Israel, Sept. 22, 2020 /PRNewswire/ -- Medasense Biometrics Ltd., developer of the NOL technology for pain-response monitoring, today announced that it has raised$18M in a series C round, from Sabadell Asabys venture...

2020-09-22 06:30 1598

Alcohol Detection Anklets Showing Promise in NZ

With COVID-19, Incidents of Alcohol Abuse Reportedly on the Rise AUCKLAND, New Zealand, Sept. 22, 2020 /PRNewswire/ -- Alcohol Detection Anklets (ADA) are garnering a lot of attention in New Zealand and Australia for helping alcohol-involved clients refrain from drinking. The anklets use transde...

2020-09-22 04:24 1322

Ortho Awarded BARDA Contract to Accelerate Antigen Test Development and Additional SARS-CoV-2 Antibody Test Milestones

RARITAN, N.J., Sept. 21, 2020 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced its continued collaboration with the Biomedical Advanced Research and Development Authority ( BARDA), part of the Office of the Assistant Secretary for Preparedness an...

2020-09-21 21:00 1555

China Pharmaceutical Holdings Co., Ltd. Has Obtained Multiple Certifications for Its Masks

HAIKOU CITY, China, Sept. 21, 2020 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced that the masks produced by ...

2020-09-21 20:30 9697

Harbour BioMed Announces Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 21, 2020 /PRNewswire/ -- Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company announced approval of two Investigational New Drug (IND) applications by the China National Medical Products Administr...

2020-09-21 20:12 1812

I-Mab Announces China NMPA Clearance for Phase 1 Clinical Trial of Lemzoparlimab in Relapsed or Refractory Advanced Lymphoma

SHANGHAI and GAITHERSBURG, Md., Sept. 21, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China ...

2020-09-21 20:00 5061

PharmAbcine expands partnership with Samsung Biologics for PMC-403

DAEJEON, South Korea, Sept. 21, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Samsung Biologics (KRX: 207940.KS) for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular ...

2020-09-21 20:00 1023

Hyde Engineering + Consulting Announces New VP of Global Engineering

BOULDER, Colorado, Sept. 21, 2020 /PRNewswire/ -- Hyde Engineering + Consulting, Inc. (Hyde) announced thatSanjay Shah has accepted the position of Vice President of Global Engineering. Sanjay, based out of Hyde's office in Ahmedabad,India, will provide subject matter expertise in conceptual an...

2020-09-21 11:30 1684

Key Milestone: The first patient successfully dosed with the candidate drug SR419 for peripheral neuropathic pain

SHANGHAI, Sept. 21, 2020 /PRNewswire/ -- Shanghai SIMR Biotechnology Co., Ltd. (hereinafter referred to as "SIMR" or "Company") announced that, the clinical trial in patients with peripheral neuropathic pain has been initiated for the candidate drug SR419, and the first patient has been successfu...

2020-09-21 10:35 881

Viva Biotech and SYNthesis Enters a Strategic Acquisition Agreement, Accelerating the Development of Global Innovative Drug R & D Service Capabilities

SHANGHAI, Sept. 21, 2020 /PRNewswire/ -- Viva Biotech (Shanghai) Co., Ltd. (hereinafter referred to as "Viva Biotech" or "The Company") entered into the Share Purchase Agreement pursuant to which Viva Biotech agreed to acquire and the Vendors agreed to collectively sell 100% of the equity interes...

2020-09-21 09:25 1652

Innovent and Lilly Jointly Release Phase 3 Results of TYVYT® (Sintilimab Injection) in Combination with GEMZAR® (Gemcitabine) and Platinum Chemotherapy as First-Line Treatment for Squamous Non-Small Cell Lung Cancer at ESMO Virtual Congress 2020

SAN FRANCISCO and SUZHOU, China, Sept. 21, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other majo...

2020-09-21 08:00 4019
12345 ... 432